Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.40 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.40 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207688 | 1.00 | NR1H2 (0.56) | NR1H2ESR2MAPTMAP4K4GRM5 | |
| SCHEMBL10255757 | 0.91 | NR1H2 (0.62) | NR1H2ESR2MAPTMAP4K4GRAMD1A | |
| SCHEMBL29508891 | 0.91 | NR1H2 (0.62) | NR1H2ESR2MAPTMAP4K4GRAMD1A | |
| SCHEMBL16691229 | 0.91 | NR1H2 (0.62) | NR1H2ESR2MAPTMAP4K4GRM5 | |
| SCHEMBL21553391 | 0.90 | NR1H2 (0.48) | NR1H2ESR2MAPTMAP4K4GRM5 | |
| SCHEMBL30207713 | 0.85 | ESR2 (0.55) | NR1H2ESR2MAPTGRM5NPC1 | |
| SCHEMBL4207648 | 0.85 | ESR2 (0.52) | NR1H2ESR2MAPTGRM5NPC1 | |
| SCHEMBL8055171 | 0.85 | ESR2 (0.55) | NR1H2ESR2MAPTGRM5NPC1 | |
| SCHEMBL13568080 | 0.84 | ESR2 (0.51) | NR1H2ESR2MAPTGRM5NPC1 | |
| SCHEMBL31484210 | 0.84 | NR1H2 (0.56) | NR1H2ESR2MAPTMAP4K4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | claimed |
| WO-2007140213-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | WO | claimed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | claimed |
| CN-115611925-B | HPK1 inhibitors and uses thereof | 轩竹生物科技股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-1899330-B9 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INT (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | disclosed |
| EP-1899330-B1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INT (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| EP-1899330-A1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | Boehringer Ingelheim International GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007140213-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | disclosed |
| WO-2007003536-A1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GNMT | NR1H2 2303/4885ESR2 2936/4885MAPT 310/4885 |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | NR1H2 1471/4885ESR2 2553/4885MAPT 426/4885 |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | NR1H2 2864/4885ESR2 2421/4885MAPT 1654/4885 |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | NR1H2 1471/4885ESR2 2553/4885MAPT 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.